Definitive Contract HHSN261201500020C

<p>This is a $299,586 firm-fixed-price contract awarded by the National Cancer Institute, a civilian federal agency, to Omicron Biochemicals, Inc. for SBIR Phase I research on the synthesis of high-mannose N-glycans. The contract is set aside for small businesses and has an ultimate completion date of June 11, 2014. Omicron Biochemicals, Inc. is a for-profit manufacturer that has previously received federal contract and grant awards.</p>

<p>This is a $999,898 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Glycobia Inc., a small business, under the SBIR Phase II program. The contract is for the development of chemically defined glycan libraries for use as reference standards and in glycomics research, under a joint NCI-NIGMS program. The contract has a small business set aside designation and runs through September 2018.</p>

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Mediomics LLC, a woman-owned small business. The contract is for the development of glycosylation-specific research under SBIR Topic 294, with a ceiling value of $148,569. SBIR contracts are set-aside for small businesses to engage in research and development for the government. This Phase I contract represents the initial research and feasibility...

This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Chemily LLC, a for-profit limited liability company. The contract has a ceiling value of $992,179.90 and is for the &quot;CHEMO-ENZYMATIC SYNTHESIS OF STRUCTURALLY DEFINED COMPLEX-TYPE N-GLYCANS.&quot; The work is to be performed in Atlanta, GA. This SBIR Phase II contract builds upon prior Phase I research and is focused on developing chemo-enzymatic...

This is a firm-fixed-price SBIR Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Chemily LLC, a small business. The contract is for the &quot;CHEMO-ENZYMATIC SYNTHESIS OF STRUCTURALLY DEFINED HYBRID AND COMPLEX-TYPE N-GLYCAN LIBRARIES&quot; and has a ceiling value of $299,544.00. The contract was awarded on September 12, 2013, with an ultimate completion date of October 30, 2014. As an SBIR Phase I contract, this award supports early-stage research and...

<p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Biotex, Inc. The contract is for the development of glycosylation-specific research, with a ceiling value of $149,919.00 and a completion date of October 14, 2012. The contract is a definitive contract with a firm fixed-price pricing type. This SBIR Phase I action is a set-aside for small businesses.</p>

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Glycohub, Inc., a woman-owned small business. The contract is for the delivery of chemically defined glycosphingolipid head groups, with a total ceiling value of $298,447.00 and a completion date of December 30, 2014. As an SBIR Phase I contract, this represents the initial research and development effort to explore the feasibility of the proposed technology....

This federal contract award, valued at $299,450.00, was issued by the National Cancer Institute, a civilian agency, to Glycobia, Inc., a for-profit limited liability company and manufacturer of goods. The contract is for a Small Business Innovation Research (SBIR) Program Phase I project titled &quot;BOTTOM-UP GLYCOENGINEERING LIBRARY OF N-GLYCANS&quot;. The contract has a firm fixed price pricing type and was awarded on September 12, 2013 with a completion date of June 30, 2014. Glycobia,...

This is a Phase II Small Business Innovation Research (SBIR) contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Siamab Therapeutics, Inc. The purpose of the contract is to develop technologies to characterize glycan moieties of glycoproteins in order to enhance the diagnostic capability of protein-based biomarkers. The specific goals include expanding the number of features for an existing sialic acid glycan array, optimizing the serum assay protocol,...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Mediomics LLC, a woman-owned small business. The contract, valued at $185,116, is a firm-fixed-price definitive contract for research and development work. The contract was awarded on September 24, 2010 and has an ultimate completion date of June 23, 2011. As an SBIR Phase I contract, it is focused on the early-stage feasibility study of a...